Long-term safety follow-up of EG110A gene therapy for overactive bladder after spinal cord injury
Follows people with overactive bladder and spinal cord injury who received EG110A earlier.
Key facts
- Who runs it
- Cyllene Therapeutics
- Where
- Ann Arbor, Downey, Houston, and Philadelphia, United StatesSee the 4 sites
- Trial code
- Registry title
- Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene Therapy
- Status
- Not yet recruiting
- Phase
- Phase 1/2
- People taking part
- 16 people, planned
- Started
- Apr 2026
- Expected to end
- Apr 2031
- Type of study
- Interventional
- Treatments tested
- Urodynamics
- EG110A
- Patient-reported Outcome
- Record updated
- 12 November 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who got at least one dose of EG110A in Study EG110A-001-01. It follows them for five years to check safety and side effects.
- Age
- 18 Years to 75 Years
- Sex
- All sexes can join
- Disease stage
- People with overactive bladder linked to spinal cord injury who took part in the earlier EG110A study, and either finished it or left it early.
- Earlier treatment
- Must have received at least one dose or injection of EG110A in Study EG110A-001-01.
Main reasons for not taking part
- Plans to join another gene therapy study that is still being tested
- An uncontrolled illness or other disorder that would make it hard to follow the study rules, as judged by the study doctor
- Current substance abuse that would make it hard to follow the study rules
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- All participants who received at least one dose/injection of EG110A in Study EG110A-001-01 and have prematurely discontinued or completed that study
Who cannot take part
- Participant plans to participate in another investigational gene therapy study
- Participant has an uncontrolled intercurrent illness, any disorder, or current substance abuse that would limit compliance with study requirements in the opinion of the investigator
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Where in United States
- University of Michigan Rogel Cancer CenterAnn Arbor, United StatesContact: John Stoffel, MDNot yet recruiting
- Rancho Los Amigos National Rehabilitation CenterDowney, United StatesContact: Evgeniy Kreydin, MDNot yet recruiting
- UTHealth Houston / TIRR Memorial HermannHouston, United StatesContact: Argyrios Stampas, MDNot yet recruiting
- Sidney Kimmel Medical CollegePhiladelphia, United StatesContact: Patrick Shenot, MDNot yet recruiting
About the trial
What the trial wants to find out
The aim of this study is to continue following participants who have received EG110A during five years to know how it is tolerated in humans, any side-effects it may cause and what might be an effective dose over five years. All participants who have received at least one dose/injection of EG110A in a previous clinical study of EG110A will be asked to roll-over to this long-term follow-up study upon either early discontinuation from, or completion of, that study.
The group in the trial
- Patients who received EG110A in a clinical study, regardless of doseTreatment being tested
Treatment: Urodynamics, EG110A, and Patient-reported Outcome
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene Therapy Expressing a Transgene Encoding the Light Chain of Botulinum Toxin F
- Plain-language title
- Long-term safety follow-up of EG110A gene therapy for overactive bladder after spinal cord injuryGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Criteria questions
- Built from NCT07227285, who can take part
- Record updated
- 12 November 2025